Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples

Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank…